ASCO 2023: Highlights and analysis

Next-generation selective RET inhibitor shows initial promise with RET-altered solid tumours

Trastuzumab deruxtecan gives strong anti-tumour activity and durable responses in multiple tumour types

HCC: Improvement in RFS for atezolizumab plus bevacizumab vs active surveillance without compromising QoL

Tackling low-volumes of clinical trials in Africa

The HypoAfrica study and AC3T research partnerships at NLCC

Achieving health equity in cancer care in the Philippines

Durable effect of imatinib and metronomic chemotherapy with capecitabine in pancreatic carcinoma

Encouraging safety and efficacy for REGN5459, a BCMA×CD3 bispecific antibody with low CD3 affinity, in patients with RRMM

Addition of Salmonella-IL2 to FOLFIRINOX for metastatic stage 4 pancreatic cancer nearly doubles median survival

Atezo plus bev demonstrates efficacy in preventing recurrence in patients with high-risk HCC

Key practices for handling difficult conversations in cancer care